104 related articles for article (PubMed ID: 33436023)
21. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS
Yao K; Sonehara Y; Nagahama F
Nihon Yakurigaku Zasshi; 2023; 158(5):408-418. PubMed ID: 37673618
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.
Bishop AJ; Amini B; Lin H; Raza SM; Patel S; Grosshans DR; Ghia A; Farooqi A; Guadagnolo BA; Mitra D; Akdemir KC; Lazar AJ; Wang WL; Alvarez-Breckenridge C; Bird J; Rhines LD; Somaiah N; Conley AP
J Immunother; 2022 Oct; 45(8):374-378. PubMed ID: 35943386
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors: Assessment of the performance and the agreement of iRECIST, irRC, and irRECIST.
Yirgin IK; Dogan I; Engin G; Vatansever S; Erturk SM
J Cancer Res Ther; 2024 Jan; 20(1):156-162. PubMed ID: 38554314
[TBL] [Abstract][Full Text] [Related]
26. Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting.
Huang H; Zhang W; Deng X; Huang H; Wang Z; Hong H; Lin T
Exp Hematol Oncol; 2024 Apr; 13(1):44. PubMed ID: 38649997
[TBL] [Abstract][Full Text] [Related]
27. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.
Chang EWY; Tan YH; Chan JY
J Hematol Oncol; 2024 Jun; 17(1):38. PubMed ID: 38824603
[TBL] [Abstract][Full Text] [Related]
28. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract][Full Text] [Related]
29. Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.
Haverkos B; Zain J; Kamdar M; Neuwelt A; Davila E; Bradeen X; Major A; Bair S; Jasem J; Smith C; Abbott D; Porcu P
Blood Adv; 2024 Feb; 8(3):708-711. PubMed ID: 38150586
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint inhibition in hematologic malignancies.
Tsumura A; Levis D; Tuscano JM
Front Oncol; 2023; 13():1288172. PubMed ID: 37920162
[TBL] [Abstract][Full Text] [Related]
31. Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma.
Zhang Q; Yin L; Lai Q; Zhao Y; Peng H
Clin Exp Med; 2023 Dec; 23(8):4219-4235. PubMed ID: 37759042
[TBL] [Abstract][Full Text] [Related]
32. Immune infiltration and drug specificity analysis of different subtypes based on functional status in angioimmunoblastic T-cell lymphoma.
Zhu S; Zhao Y; Xing C; Guo W; Huang Z; Zhang H; Yin L; Ruan X; Li H; Cheng Z; Wang Z; Peng H
Heliyon; 2023 Aug; 9(8):e18836. PubMed ID: 37576233
[TBL] [Abstract][Full Text] [Related]
33. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH; Dahi PB; Redd RA; McDonough MM; Chen YB; DeFilipp Z; Herrera AF; Fisher DC; LaCasce AS; Odejide OO; Ng SY; Jacobson CA; Merryman RW; Kim AI; Nieto YL; Sauter CS; Shah GL; Zain JM; Armand P; Jacobsen ED
Blood; 2023 Aug; 142(7):621-628. PubMed ID: 37319432
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi Y; Cui J; Zhou H; Zhang X; Zou L; Cao J; Gao Y; Jin C; Li X; Liu H; Peng Z; Xie L; Zhang H; Zhang W; Zhang H; Zhong L; Zhou F; Guo G; He W
Cancer Immunol Immunother; 2023 Sep; 72(9):2991-3002. PubMed ID: 37289256
[TBL] [Abstract][Full Text] [Related]
35. Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies.
Braun T; Schrader A
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173999
[TBL] [Abstract][Full Text] [Related]
36. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target.
Carty SA; Murga-Zamalloa CA; Wilcox RA
Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):561-574. PubMed ID: 37142534
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.
Liu Y; Song Y; Zuo S; Zhang X; Liu H; Wang J; Wang J; Tang Y; Zheng W; Ying Z; Ping L; Zhang C; Wu M; Zhu J; Xie Y
Front Immunol; 2023; 14():1128172. PubMed ID: 37081867
[TBL] [Abstract][Full Text] [Related]
38. Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.
Huang H; Tao R; Hao S; Yang Y; Cen H; Zhou H; Guo Y; Zou L; Cao J; Huang Y; Jin J; Zhang L; Yang H; Xing X; Zhang H; Liu Y; Ding K; Qi Q; Zhu X; Zhu D; Wang S; Fang T; Dai H; Shi Q; Yang J
J Clin Oncol; 2023 Jun; 41(16):3032-3041. PubMed ID: 36996373
[TBL] [Abstract][Full Text] [Related]
39. Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.
Zhang C; Wang L; Xu C; Xu H; Wu Y
Front Pharmacol; 2023; 14():1079924. PubMed ID: 36959853
[TBL] [Abstract][Full Text] [Related]
40. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.
Yap DRY; Lim JQ; Huang D; Ong CK; Chan JY
Front Immunol; 2023; 14():1068662. PubMed ID: 36776886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
